7RYTM : Analyst Expectations For Rhythm Pharmaceuticals&#...
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.89, with a ...
Seeking Alpha28d
Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven
Rhythm Pharmaceuticals' 01/2025 presentation ... the first and only precision medicine to target impairment of the hypothalamic MC4R pathway, a root cause of hyperphagia and obesity due to BBS ...
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...
New York Post23d
Daylight saving time is this week — 3 tips to ease into it so you don’t ruin your sleep
Try to embrace morning light in the days leading up to DST to maintain a healthy circadian rhythm. Dr. Alcibiades Rodriguez, director of sleep medicine at NYU Grossman School of Medicine ...
Hosted on MSN14d
Unlocking a common cause of ataxia: A step toward effective treatment
a loss of motor rhythm and precision. Dr. Ming-Kai Pan at National Taiwan University College of Medicine and Dr. Sheng-Han Kuo at Columbia University have identified a shared pathological feature ...